Shanghai Fosun Pharma, the subsidiary of Fosun International, and Pramerica-Fosun China Opportunity Fund will pay $240 million for up to 95.6% of Israel-based Alma Lasers.
It is Fosun Pharma’s first international healthcare acquisition since its Hong Kong H-share listing in October last year. According to IMS Health Incorporated, Fosun was one of the top five domestic companies in China by revenue in the pharmaceutical manufacturing segment in 2011.
China is one of Alma Lasers’ main markets, where the firm has been active for the past decade and has become a leader in the high-end market segment for energy-based aesthetic medical devices.
“Fosun’s successful...
¬ Haymarket Media Limited. All rights reserved.
